TY - JOUR T1 - Somatostatin. Its possible role in carbohydrate homeostasis and the treatment of diabetes mellitus. A1 - Gerich,J E, PY - 1977/5/1/pubmed PY - 1977/5/1/medline PY - 1977/5/1/entrez SP - 659 EP - 66 JF - Archives of internal medicine JO - Arch Intern Med VL - 137 IS - 5 N2 - Somatostatin, a peptide inhibitor of growth hormone release originally isolated from the hypothalamus, is also present in D cells of pancreatic islets. Its ability to inhibit the secretion of insulin and glucagon suggests that it may be a local regulator of pancreatic A- and B-cell function. Studies using synthetic somatostatin have provided evidence that glucagon is a physiologically important hormone that exacerbates the consequences of insulin deficiency in human diabetes mellitus. The ability of somatostatin to diminish both fasting and post-prandial hyperglycemia and to forestall the development of ketoacidosis after withdrawal of insulin in insulin-dependent diabetics suggests a potential therapeutic use of this agent in diabetes. Presently, however, its short half-life and diverse actions preclude such use and have prompted the search for more specific and longer-acting analogs. SN - 0003-9926 UR - https://www.unboundmedicine.com/medline/citation/324423/Somatostatin__Its_possible_role_in_carbohydrate_homeostasis_and_the_treatment_of_diabetes_mellitus_ L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/vol/137/pg/659 DB - PRIME DP - Unbound Medicine ER -